Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Arch Med Res
; 51(6): 595-597, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-793360
ABSTRACT
Presently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT or MAPK/NF-κB-IL-6 pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT or MAPK/NF-κB-IL-6 signaling pathway. It finally stops the cytokine storm syndrome. However, we need to understand that how tocilizumab is bound with mIL-6R or sIL-6R. Similarly, we also need to understand more about the real molecular mechanism of activity of tocilizumab.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Receptors, Interleukin-6
/
Antibodies, Monoclonal, Humanized
/
Cytokine Release Syndrome
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Arch Med Res
Journal subject:
Medicine
Year:
2020
Document Type:
Article
Affiliation country:
J.arcmed.2020.05.009
Similar
MEDLINE
...
LILACS
LIS